<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The prostacyclin analog, beraprost <z:chebi fb="199" ids="26708">sodium</z:chebi> (BPS), was examined for its potential to improve the symptoms of <z:hpo ids='HP_0001513'>obesity</z:hpo>-type <z:mp ids='MP_0002055'>diabetes</z:mp> (i.e., <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, histopathologic changes, and <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: <z:mp ids='MP_0001261'>Obese</z:mp> <z:chebi fb="3" ids="16646">Zucker</z:chebi> rats, an experimental model of genetic <z:hpo ids='HP_0001513'>obesity</z:hpo>-induced type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, were repeatedly administered BPS at oral doses of 0.2 or 0.6 mg x kg(-1) x day(-1) b.i.d. for 12 weeks, and serum chemistry, urinalysis, and histopathologic examination were performed </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: BPS dose-dependently suppressed serum <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, and cholesterol levels in <z:mp ids='MP_0001261'>obese</z:mp> animals </plain></SENT>
<SENT sid="3" pm="."><plain>In oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test, BPS suppressed the post-<z:chebi fb="105" ids="17234">glucose</z:chebi>-loading elevation of serum <z:chebi fb="105" ids="17234">glucose</z:chebi> in a dose-dependent manner </plain></SENT>
<SENT sid="4" pm="."><plain>Urinary N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-beta-D-glucosaminidase was significantly lower in BPS-treated <z:mp ids='MP_0001261'>obese</z:mp> animals compared with control animals, although no significant differences were observed in urinary protein levels between the BPS-treated groups and the control group </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, histopathologic examination revealed significant protective effects of BPS against <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disorder</z:e> in <z:mp ids='MP_0001261'>obese</z:mp> animals </plain></SENT>
<SENT sid="6" pm="."><plain>Histopathologically, BPS also inhibited the progression of <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo>, <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> of adipose tissue, and <z:hpo ids='HP_0100732'>pancreatic fibrosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, thermographic analysis of the hind limb sole skin surface indicated a significant increase in temperature in BPS-treated animals, compared with control animals, which was likely due to improved blood circulation by administration of BPS </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: BPS suppressed the pathogenesis and development of <z:mp ids='MP_0002055'>diabetes</z:mp> and its complication, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, which was presumably accompanied by improving <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in <z:mp ids='MP_0001261'>obese</z:mp> <z:chebi fb="3" ids="16646">Zucker</z:chebi> rats </plain></SENT>
</text></document>